David E. Kaplan, MD, MSc, FACP, FAASLD, AGAF
Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Research interests: translational research in therapy for liver cancer, epidemiological research into the relationship of medication exposures and the natural history of chronic liver disease, and clinical research related to cirrhosis
Dr. David E. Kaplan is an Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. He obtained his medical degree at UT Southwestern and completed internal medicine training at Johns Hopkins University. He completed Gastroenterology and Hepatology fellowship training at the University of Pennsylvania before appointment to the faculty at Penn. Since 2011, Dr. Kaplan has served as Director of Hepatology at the Corporal Michael J. Crescenz Veterans Administration Medical Center and in 2022 was appointed as Section Chief of Hepatology at the University of Pennsylvania.
Dr. Kaplan currently collaborates with Dr. Terence Gade to maintain a VA-funded translational research laboratory focusing on immunopathogenesis of hepatocellular carcinoma and the development of personalized medicine platforms for liver cancer therapy via PDX models. For more than 10 years, Dr. Kaplan has undertaken multiple large database studies studying natural history of pharmaco-epidemiological associations in cirrhosis and hepatocellular carcinoma with a long-standing collaboration with Dr. Tamar Taddei at Yale, establishing the Veterans Outcomes and Cost Associated with Liver disease (VOCAL) consortium. Dr. Taddei and Dr. Kaplan are currently national co-PIs for a 10-center VA study evaluating the effect of simvastatin on reducing decompensation events in patients with cirrhosis (NCT03654053). Dr. Kaplan and multiple local collaborators have used VOCAL data to better understand outcomes, cost and care delivery in viral hepatitis, transplant utility and liver cancer.
Dr. Kaplan is a Fellow of the AASLD, AGA and ACP. He has been involved in multiple efforts for these societies including chairing the AASLD Foundation Research Awards Committee (2019-2021) and he is currently co-chair of the Practice Guidance Writing Committee for “Portal Hypertension in Cirrhosis” (2021-2022). To date, he has over 130 peer-reviewed publications related to GI and liver diseases.
Editorial Board
Terms of Appointment: August 2022 - July 2024